Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India delays COVID-19 vaccine supplies to WHO-backed COVAX, sources say

10/20/2021 | 01:10am EST

NEW DELHI, Oct 19 (Reuters) - India has delayed committing supplies of vaccine to the COVAX global sharing effort, two sources told Reuters on Tuesday, a day after one of its key backers, the WHO, said the agency could not "cut corners" to approve a domestically developed vaccine.

The world's biggest vaccine maker resumed exports of COVID-19 doses this month for the first time since April. It has sent about 4 million https://www.reuters.com/world/india/india-resumes-vaccine-exports-domestic-stocks-build-up-officials-2021-10-13to countries such as neighbouring Bangladesh and Iran, but none to COVAX.

Delayed supplies to COVAX could disrupt inoculation drives in many African nations that rely on it for vaccines.

On Monday, in the run-up to an Oct. 26 meeting on Covaxin, India's first domestically developed COVID-19 vaccine, the World Health Organization (WHO) said it could not "cut corners https://www.reuters.com/business/healthcare-pharmaceuticals/who-expects-more-information-indias-bharat-biotech-its-covid-19-vaccine-2021-10-18 " in the approval decision.

One of the sources said it was "frustrating" that India had yet to confirm any supply to COVAX, despite a promise by the health minister last month to meet the commitment to COVAX and others during the quarter to December.

The sources, who have been briefed on the export talks, declined to be identified as they were not authorised to speak on the subject.

"We are still waiting for confirmation on when and how many doses we can expect when exports do resume, and are not aware of any specific delay," COVAX co-lead GAVI, the Global Alliance for Vaccines and Immunization, said in an email.

"Indian vaccines have a powerful role to play" in ending the pandemic, it added.

India's health ministry, WHO and the Serum Institute of India (SII), which is the world's biggest maker of vaccines, did not respond to requests for comment.

SII, contracted to supply hundreds of millions of doses of a version of the AstraZeneca vaccine to COVAX and countries such as Bangladesh, has more than tripled its output of the vaccine since April, to reach 220 million doses a month.

Indian government officials have said they are confident the WHO will soon approve emergency use of Covaxin, which accounts for 11% of the 990 million doses India has injected, with the rest mostly from AstraZeneca.

A few weeks ago, Adar Poonawalla, the chief executive of SII, told the Telegraph newspaper that the company would resume exports to COVAX in October.

"Initially these supplies will be small, but by January 2022, once we have satisfied domestic demands ... we will see large volumes go to COVAX," he added.

Before India halted overseas vaccine shipments in April to fill domestic demand, it donated or sold more than 66 million COVID-19 doses, including Covaxin.

(Reporting by Krishna N. Das; Additional reporting by Sanjeev Miglani; Editing by Clarence Fernandez)


ę Reuters 2021
All news about ASTRAZENECA PLC
09:06aCovid-19 - Nigeria Approves Booster Doses for Enhanced Protection
AQ
12/03AstraZeneca Explores Listing of Newly-Created Vaccines Unit
MT
12/03AstraZeneca Reportedly Weighs Listing of Newly-Created Vaccines Unit
MT
12/03European Stocks Close Lower After Disappointing US Jobs Data
MT
12/03Sobi Down 23% After AstraZeneca Said to Block Advent, GIC's Takeover Bid
MT
12/03Hutchmed's Two Cancer Therapies Included in China's Drug Reimbursement List
MT
12/03ASTRAZENECA : reinforces leadership in breast cancer at SABCS 2021 with new data underscor..
PU
12/02Pfizer-BioNTech, Moderna's COVID-19 Jabs Offer Best Immunity Boost, UK Study Says
MT
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/01Scientists Discover Cause Behind Blood Clot Formation After AstraZeneca Vaccine
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2021 35 919 M - -
Net income 2021 3 423 M - -
Net Debt 2021 25 253 M - -
P/E ratio 2021 36,9x
Yield 2021 2,60%
Capitalization 168 B 168 B -
EV / Sales 2021 5,38x
EV / Sales 2022 4,40x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Last Close Price 108,38 $
Average target price 137,48 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC11.84%167 779
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641